Homepage

Artivion, Inc.

AORT NYSE Categories PDF
Healthcare · Medical - Devices · United States · Updated May 10, 8:16pm
$25.41
Price
$1.2B
Market Cap
1,600
Employees
1.40
Beta
James Patrick Mackin
CEO
Business Description

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Business History
Price Overview
Last updated: May 11, 2026 1:56pm (just now)
$23.86
-1.55 (-6.10%)
Day Range
$23.42 – $25.59
52-Week Range
$19.16 – $48.25
50-Day MA
$36.29
200-Day MA
$40.71
Volume
1,068,670.00
Analyst Price Targets
Low $51.00
Consensus $53.00
High $55.00
(9 analysts)
Share Structure
Outstanding 48,496,000.00
Float 46,023,465.00
Free Float 94.9%
High free float — 94.9% of shares trade freely, ~5.1% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
API
Stock Price / EPS (Diluted)
98.12
Stock Price: $25.41
EPS (Diluted): 0.22
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
4.61
Stock Price: $25.41
Total Equity: $448.23M
Shares: 47,162,000
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
20.59
Market Cap: $1.23B
Total Debt: $254.92M
Cash: $64.91M
EBITDA: $49.20M
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
$2.3B
Market Cap: $1.23B
Total Debt: $254.92M
Cash: $64.91M
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
61.3%
Gross Profit: $270.45M
Revenue: $441.33M
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
6.1%
Operating Income: $26.75M
Revenue: $441.33M
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
2.2%
Net Income: $9.77M
Revenue: $441.33M
ROE (Profit from shareholder equity)
API
Net Income / Total Equity
2.7%
Net Income: $9.77M
Total Equity: $448.23M
ROIC (Profit from all invested capital)
API
NOPAT / Invested Capital
2.9%
Operating Income: $26.75M
Tax Rate: 33.9%
Equity: $448.23M
Total Debt: $254.92M
Cash: $64.91M
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
2.99
Current Assets: $303.55M
Current Liabilities: $101.56M
Debt/Equity (Leverage — debt vs equity)
CALC
Total Debt / Total Equity
0.57
Short-Term Debt: $5.38M
Long-Term Debt: $249.54M
Total Debt: $254.92M
Total Equity: $448.23M
Rev/Share (Top-line per share)
CALC
Revenue / Shares Outstanding
$9.36
Revenue: $441.33M
Shares: 47,162,000
Book Value/Share (Net assets per share)
CALC
(Total Assets - Total Liabilities) / Shares
$9.50
Total Equity: $448.23M
Shares: 47,162,000
FCF/Share (Real cash generated per share)
CALC
(Operating Cash Flow + CapEx) / Shares
$-0.02
Operating CF: $38.13M
CapEx: -$39.04M
Shares: 47,162,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $25.41
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $9.77M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares AORT against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Metric 2021 2022 2023 2024 2025
Revenue $298.8M $313.8M $354.0M $388.5M $441.3M
Cost of Revenue $101.3M $111.3M $124.8M $139.8M $170.9M
Gross Profit $197.5M $202.5M $229.2M $248.8M $270.5M
Operating Expenses $189.4M $196.3M $223.4M $209.9M $243.7M
Operating Income $8.1M $6.2M $5.7M $38.9M $26.7M
Net Income -$14.8M -$19.2M -$30.7M -$13.4M $9.8M
EBITDA $26.0M $25.7M $26.8M $51.0M $49.2M
EPS $-0.38 $-0.48 $-0.75 $-0.32 $0.22
EPS (Diluted) — — — — —
Balance Sheet (Annual)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $55.0M $39.4M $58.9M $53.5M $64.9M
Total Current Assets $247.7M $247.3M $280.7M $290.1M $303.6M
Total Assets $793.1M $762.8M $792.4M $789.1M $884.8M
Current Liabilities $45.0M $49.7M $57.9M $66.8M $101.6M
Long-Term Debt $307.5M $306.5M $305.5M $314.2M $249.5M
Total Liabilities $492.3M $478.5M $510.6M $512.9M $436.6M
Total Equity $300.7M $284.3M $281.8M $276.2M $448.2M
Retained Earnings $2.0M -$17.2M -$47.9M -$61.3M -$51.5M
Cash Flow (Annual)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow -$2.6M -$5.2M $18.8M $22.2M $38.1M
Capital Expenditure -$13.1M -$10.7M -$7.4M -$11.2M -$39.0M
Free Cash Flow -$15.7M -$15.9M $11.4M $11.0M $-911,000
Acquisitions (net) $0 $0 $0 $0 $0
Debt Repayment — — — — —
Dividends Paid — — — — —
Stock Buybacks -$1.9M -$1.8M $-559,000 $0 $0
Net Change in Cash -$6.9M -$15.7M $19.6M -$5.5M $11.4M
Analyst Estimates (Annual)
Metric 2027 2028 2029 2030
Revenue $541.3M
$540.0M – $542.5M
 $601.2M
$591.5M – $611.0M
 $677.9M
$669.5M – $686.6M
 $763.9M
$754.4M – $773.7M
EBITDA $52.8M
$52.6M – $52.9M
 $58.6M
$57.6M – $59.6M
 $66.1M
$65.3M – $66.9M
 $74.5M
$73.5M – $75.4M
Net Income $22.5M
$22.1M – $22.8M
 $42.6M
$35.7M – $45.6M
 $56.1M
$55.2M – $57.1M
 $74.0M
$72.9M – $75.3M
EPS — — — —
Growth Trends (YoY %)
Metric 2022 2023 2024 2025
Revenue Growth +5.0% +12.8% +9.8% +13.6%
Gross Profit Growth +2.5% +13.2% +8.6% +8.7%
Operating Income Growth -23.6% -7.4% +577.0% -31.2%
Net Income Growth -29.4% -59.9% +56.5% +173.1%
EBITDA Growth -1.4% +4.3% +90.3% -3.5%
Insider Trading (Recent)
Date Insider Type Shares Price Value
2026-03-02 Horton Amy A-Award 7,475.00 $0.00 $0
2026-03-03 Horton Amy S-Sale 901.00 $37.78 $34,036
2026-03-02 Holloway Jean F A-Award 27,795.00 $0.00 $0
2026-03-03 Holloway Jean F S-Sale 3,843.00 $37.78 $145,172
2026-03-04 Holloway Jean F S-Sale 8,962.00 $38.00 $340,556
2026-03-02 Stanton Marshall S. A-Award 21,838.00 $0.00 $0
2026-03-03 Stanton Marshall S. S-Sale 2,149.00 $37.78 $81,180
2026-03-02 Davis John E A-Award 28,845.00 $0.00 $0
2026-03-03 Davis John E S-Sale 4,573.00 $37.78 $172,748
2026-03-02 Berry Lance A A-Award 40,874.00 $0.00 $0
2026-03-03 Berry Lance A S-Sale 6,316.00 $37.78 $238,591
2026-03-02 Mackin James P A-Award 116,948.00 $0.00 $0
2026-03-03 Mackin James P S-Sale 17,887.00 $37.78 $675,692
2026-03-02 Horton Amy S-Sale 641.00 $38.02 $24,374
2026-03-02 Stanton Marshall S. S-Sale 1,513.00 $38.02 $57,532
2026-03-02 Mackin James P S-Sale 14,911.00 $38.02 $566,989
2026-03-02 Holloway Jean F S-Sale 2,183.00 $38.02 $83,008
2026-03-02 Berry Lance A S-Sale 5,178.00 $38.02 $196,893
2026-03-02 Davis John E S-Sale 2,784.00 $38.02 $105,861
2026-02-24 Horton Amy A-Award 5,658.00 $0.00 $0
Dividend History (Last 20)
Date Dividend Declaration Record Payment
2015-12-09 $0.03 2015-10-22 2015-12-11 2015-12-18
2015-09-09 $0.03 2015-07-22 2015-09-11 2015-09-18
2015-06-10 $0.03 2015-05-21 2015-06-12 2015-06-19
2015-03-11 $0.03 2015-02-13 2015-03-13 2015-03-20
2014-12-10 $0.03 2014-10-23 2014-12-12 2014-12-19
2014-09-10 $0.03 2014-07-30 2014-09-12 2014-09-19
2014-06-11 $0.03 2014-05-22 2014-06-13 2014-06-20
2014-03-12 $0.03 2014-02-19 2014-03-14 2014-03-21
2013-12-11 $0.03 2013-11-21 2013-12-13 2013-12-20
2013-09-11 $0.03 2013-08-21 2013-09-13 2013-09-20
2013-06-12 $0.03 2013-05-28 2013-06-14 2013-06-21
2013-03-12 $0.03 2013-02-13 2013-03-14 2013-03-21
2012-12-12 $0.03 2012-11-19 2012-12-14 2012-12-21
2012-09-12 $0.03 2012-08-21 2012-09-14 2012-09-21
Community AI Feedback
Sign in to Contribute
No community reviews yet for AORT. Be the first — export the analysis to your AI and contribute back.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27